Dutch company Factory CRO chooses US-based AmeriStart
AmeriStart announced that it has signed a sales, marketing, and business development services contract with Factory CRO, a leading international clinical research organization that specializes in conducting medical device studies for FDA and EU approvals.
Dutch company Factory CRO chooses US-based AmeriStart
to promote its medical device clinical services to the American market
FOR IMMEDIATE RELEASE
Charlotte, NC (August 21, 2008): AmeriStart announced today that it has signed a sales, marketing, and business development services contract with Factory CRO, a leading international clinical research organization that specializes in conducting medical device studies for FDA and EU approvals. AmeriStart will promote Factory CRO’s considerable clinical research capabilities in the growing North American medical device market.
“Factory provides pan-European capabilities and access to key surgeons and clinics – exactly what US device developers need for a faster study start and faster marketing approval,” stated Dirk Meijer, CEO of Factory CRO from their headquarters in The Netherlands.
“Our team of experienced physicians, clinicians, and medical device professionals has, over the past 20 years, conducted clinical studies for more than 50 American medical device manufacturers. Now, with a representative office and AmeriStart’s organizational support, we hope to expand and improve our standing in the USA marketplace.”
AmeriStart CFO David Worrell noted, “Factory CRO has world-class capabilities in the key therapeutic areas of diabetes, wound healing, and orthopedics. Because Factory understands the regulatory environments across Europe, they are often able to start a clinical trial in as little as eight weeks. And, Factory has the added benefit of an operational center in the Dutch Antilles, which has a large diabetic population and is conveniently located in the Eastern US time zone.”
Factory CRO is the latest addition to the AmeriStart portfolio of world-class Contract Research Organizations (CROs) and other service providers to the Life Science industry.
AmeriStart will apply and promote Factory’s expertise to companies seeking both CE Marks and FDA approvals, including 510(k) designations. Further information on Factory CRO’s clinical capabilities can be found online at www.factory-cro.com.
About AmeriStart
From headquarters in Charlotte, NC, AmeriStart helps foreign companies enter and succeed in the competitive US marketplace. AmeriStart provides sales, marketing, and strategic business development services that help companies overcome cultural, language and geographic barriers to ramp their sales quickly. Details are available at www.AmeriStart.com.
About Factory CRO
Factory-CRO, established in 1988, is a full service Contract Research Organization offering regulatory, pre-clinical, and clinical trial services for medical devices, medical device/drug combinations, biologicals and cell-based products. Based in Bilthoven, The Netherlands, Factory CRO maintains relationships with sites across Europe and North America.
Because their network includes surgeons from many specialties, Factory CRO ensures that sponsors work with the best investigators for their study – resulting in both wide market recognition and strong patient recruitment. Factory CRO also maintains an office in the island of Curacao (The Dutch Antilles), where they specialize in trials related to diabetic wound healing. www.factory-cro.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
